Belt and Road Summit 2025- Deal-making

10–16 Sept 2025 | China (Hong Kong)

Haiyang Wang

CEO

Shanghai Haiju Biotechnology Co., Ltd.

Shanghai, China

9 profile visitsProject Owner

With 15 years of experience in novel drug R&D,focusing on oncology leading three Class 1.1 new drug projects into advanced clinical stages

My organisation

Pipeline one:HJ-550 introduces targeted design into platinum-based drugs for the first time, significantly outperforming current first-line chemotherapy drugs (such as traditional platinum drugs, paclitaxel, and adriamycin) in treating highly lethal cancers like lung cancer, gastric cancer, and triple-negative breast cancer. Pipeline two:HJ-462 features protein kinase inhibitors with ingenious molecular designs that avoid defects in drug metabolism within the body, resulting in excellent safety and remarkable efficacy (achieving 100% tumor regression in liver cancer, gastric cancer, and lung cancer models caused by MET amplification, effectively curing these conditions).
Read more

About me

If you are interested in new anti-tumor drugs,

you are welcome to contact us (haiju_biotech@zohomail.cn

WeChat ID: haiju3223

and phone number: 13472810300.

Marketplace (2)

  • Project

    Novel Platinum-Based Drug Targeting Tumor Microenvironment (HJ-550 )

    HJ-550 introduces targeted design into platinum-based drugs for the first time

    • Yes
    • Equity
    • Bio-Tech
    • Technology
    • Joint Venture
    • Legal Advisory
    • Private Project
    • R&D Cooperation
    • Seed & Pre-Series
    • Financial Services
    • Investment Banking
    • Business Valuation
    • Corporate Services
    • Open for Negotiation
    • Professional Services
    • Minority Shareholdings
    • Feasibility Study Completed
    • Private Equity & Venture Capital
    Author

    Haiyang Wang

    CEO at Shanghai Haiju Biotechnology Co., Ltd.

    Shanghai, China

  • Project

    Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)

    protein kinase inhibitors with ingenious molecular designs

    • Yes
    • Equity
    • Bio-Tech
    • Technology
    • Joint Venture
    • Private Project
    • R&D Cooperation
    • Seed & Pre-Series
    • Financial Services
    • Business Valuation
    • Corporate Services
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • Minority Shareholdings
    • Institutional Investment
    • Feasibility Study Completed
    • Market Entry Strategic Analysis
    • Private Equity & Venture Capital
    Author

    Haiyang Wang

    CEO at Shanghai Haiju Biotechnology Co., Ltd.

    Shanghai, China